title: [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
abstract: To cure intrahepatic cholangiocarcinoma (ICC), only a surgical resection is the potential treatment at present. However, recurrence tumors in residual liver and/or distant organs even after curative surgery are commonly experienced in clinical course. Unfortunately the potential treatment for this recurrent disease is not established at present. Accordingly, the prognosis of this recurrent ICC is extremely poor. Here, we report the prolonged survival case with recurrent ICC after hepatic resection followed by combined therapy of intrahepatic arterial infusion with CDDP and S-1 administration. The patient was a 71-year-old female. She had been treated for hepatitis B for last 5 years. After that, liver tumor of 30 mm in diameter was detected in S1/8 by abdominal CT examination. Subsequently, caudate lobectomy and partial resection of Segment 8 were performed under the diagnosis of Hepatocellular carcinoma in Osaka university hospital. The pathological stage was T2N0M0, Stage II with moderately differentiated intrahepatic cholangiocarcinoma. As the recurrence tumor was found in Segment 4 of residual liver, we started a treatment with intrahepatic arterial infusion with CDDP and S-1 administration, immediately. These combined therapy displayed beneficial effects and a recurrent liver tumor was well controlled. At present, this patient is still survived for over 5 years after the operation.
authors.affiliation: Dept. of Gastroenterological Surgery, Graduated School of Medicine, Osaka University.
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Tanida
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tanemura
authors.forename: Shogo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Wada
authors.forename: Shigeru
authors.initials: S
authors.lastname: Marubashi
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Eguchi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Umeshita
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Yuichirou
authors.initials: Y
authors.lastname: Doki
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000601:surgery; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D009364:Neoplasm Recurrence, Local; D010094:Oxonic Acid / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin